Cargando…
Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study
The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of cancer patients provides an invaluable resource that can be used for diagnosis and prognosis and to evaluate response to treatments. Lung cancer has seen in the last years a revolution in treatment st...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354425/ https://www.ncbi.nlm.nih.gov/pubmed/37476385 http://dx.doi.org/10.3389/fonc.2023.1197037 |
_version_ | 1785074925811269632 |
---|---|
author | Brooks, Helen Li, Ling Addeo, Alfredo Stevens, Megan Comins, Charles Oltean, Sebastian |
author_facet | Brooks, Helen Li, Ling Addeo, Alfredo Stevens, Megan Comins, Charles Oltean, Sebastian |
author_sort | Brooks, Helen |
collection | PubMed |
description | The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of cancer patients provides an invaluable resource that can be used for diagnosis and prognosis and to evaluate response to treatments. Lung cancer has seen in the last years a revolution in treatment strategy with the use of several classes of EGFR inhibitors. However, almost invariably, resistance to such therapies appears. In this paper, we describe a pilot, longitudinal study with 20 patients with confirmed EGFR mutations in tissue biopsy for lung cancer. The objective of the study was to determine whether ctDNA from plasma and/or urine could be used to monitor the EGFR mutational status of patients with confirmed EGFR mutation-positive non-small cell lung cancer (NSCLC) during treatment with EGFR inhibitors. Blood and urine were collected monthly over periods ranging from 6 to 16 months. CtDNA was analysed in each patient for the presence of several known mutations that predispose to resistance to EGFR inhibitors. We have proven that serial monitoring of ctDNA from both plasma and urine is feasible and that patients are willing to participate in this process. We have also shown that longitudinal ctDNA monitoring may detect resistance mutations before the development of radiological and clinical disease progression. |
format | Online Article Text |
id | pubmed-10354425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103544252023-07-20 Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study Brooks, Helen Li, Ling Addeo, Alfredo Stevens, Megan Comins, Charles Oltean, Sebastian Front Oncol Oncology The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of cancer patients provides an invaluable resource that can be used for diagnosis and prognosis and to evaluate response to treatments. Lung cancer has seen in the last years a revolution in treatment strategy with the use of several classes of EGFR inhibitors. However, almost invariably, resistance to such therapies appears. In this paper, we describe a pilot, longitudinal study with 20 patients with confirmed EGFR mutations in tissue biopsy for lung cancer. The objective of the study was to determine whether ctDNA from plasma and/or urine could be used to monitor the EGFR mutational status of patients with confirmed EGFR mutation-positive non-small cell lung cancer (NSCLC) during treatment with EGFR inhibitors. Blood and urine were collected monthly over periods ranging from 6 to 16 months. CtDNA was analysed in each patient for the presence of several known mutations that predispose to resistance to EGFR inhibitors. We have proven that serial monitoring of ctDNA from both plasma and urine is feasible and that patients are willing to participate in this process. We have also shown that longitudinal ctDNA monitoring may detect resistance mutations before the development of radiological and clinical disease progression. Frontiers Media S.A. 2023-07-05 /pmc/articles/PMC10354425/ /pubmed/37476385 http://dx.doi.org/10.3389/fonc.2023.1197037 Text en Copyright © 2023 Brooks, Li, Addeo, Stevens, Comins and Oltean https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Brooks, Helen Li, Ling Addeo, Alfredo Stevens, Megan Comins, Charles Oltean, Sebastian Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title | Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title_full | Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title_fullStr | Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title_full_unstemmed | Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title_short | Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study |
title_sort | detection of genomic mutations in blood and urine free circulating tumour dna in patients with inoperable and metastatic lung adenocarcinoma harbouring an egfr mutation in tissue: a uk pilot study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354425/ https://www.ncbi.nlm.nih.gov/pubmed/37476385 http://dx.doi.org/10.3389/fonc.2023.1197037 |
work_keys_str_mv | AT brookshelen detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy AT liling detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy AT addeoalfredo detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy AT stevensmegan detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy AT cominscharles detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy AT olteansebastian detectionofgenomicmutationsinbloodandurinefreecirculatingtumourdnainpatientswithinoperableandmetastaticlungadenocarcinomaharbouringanegfrmutationintissueaukpilotstudy |